RIPK4 and neoplasm: The most prevalent tumor suppressors identified were ADAM10, AJUBA, receptor interacting serine/threonine kinase 4 (RIPK4), NOTCH2, and NOTCH3, which were all shown to converge on the NOTCH pathway.